ABSTRACT
Venous thromboembolism (VTE) occurs at an increased incidence in cancer patients. A cancer-related hypercoagulable state has been considered to play role in this phenomenon. Preclinical data suggest an association between tumor expression of MET proto-oncogene (MET) and a hypercoagulable state, resulting in VTE. We investigated this association in this retrospective study. Thirty-five cancer patients with documented VTE and no relevant predisposing factors were compared with 35 matched cancer patients without VTE who served as controls. Pathology specimens of all patients and controls were stained by immunohistochemistry (IHC) for MET protein. Intensity of reactivity to the MET antibody was read as 0 (negative), 1+ (equivocal), and 2+ (positive). The pathologists were blinded to the patient VTE status. The MET reactivity in tissue sections were compared between the two cohorts. No significant difference was observed between the two groups for MET expression. This study's findings indicate no association between the reactivity for MET protein as measured through an immunohistochemical technique, and the incidence of VTE in cancer patients.
Subject(s)
Neoplasms/complications , Proto-Oncogene Proteins c-met/analysis , Receptors, Growth Factor/analysis , Venous Thromboembolism/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Immunohistochemistry , Incidence , Male , Middle Aged , Neoplasms/pathology , Proto-Oncogene Mas , Proto-Oncogene Proteins c-met/physiology , Receptors, Growth Factor/physiology , Retrospective Studies , Risk Factors , Venous Thromboembolism/epidemiologyABSTRACT
Synovial sarcoma of the kidney is a recently reported neoplasm. Only 33 cases have been reported in published studies. It is a difficult neoplasm to differentiate from other renal masses and requires specific molecular/genetic testing. Currently, no treatment guidelines have been established. Accurate diagnosis is imperative to implement effective therapy.
Subject(s)
Kidney Neoplasms/diagnosis , Kidney Neoplasms/pathology , Sarcoma, Synovial/diagnosis , Sarcoma, Synovial/pathology , Adolescent , Humans , Immunohistochemistry , Kidney/pathology , Laparoscopy/methods , Male , Medical Oncology/methods , Nephrectomy/methods , Tomography, X-Ray Computed/methodsABSTRACT
A 71-year-old man with duodenal gastrin cell tumor was being evaluated for residual/metastatic disease. Somatostatin receptor scintigraphy (SRS) identified a 2-cm area of focal uptake within the head of the pancreas, consistent with a pancreatic neuroendocrine tumor. Pathological examination did not reveal any malignancy within the pancreas. Instead, the pancreatic head showed pancreatic polypeptide cell hyperplasia. Strong and diffuse immunoreactivity to somatostatin receptor 2A antibody by immunoperoxidase staining confirmed that the lesion correlated with the site of radioactive tracer (Indium-111 pentetreotide) uptake seen on SRS. The current report therefore presents pancreatic polypeptide cell hyperplasia as a new pitfall in SRS.
